PHRM.CN Stock - PharmaTher Holdings Ltd.
Unlock GoAI Insights for PHRM.CN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-711 | $-1,422 | $-1,777 | $-355 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-1,523,637 | $-3,044,080 | $-3,959,843 | $-4,102,354 | $-2,816,833 |
| Net Income | $-1,526,106 | $-3,115,340 | $-6,416,319 | $-4,010,636 | $2.66M |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.02 | $-0.04 | $-0.07 | $-0.05 | $0.04 |
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
Visit WebsiteEarnings History & Surprises
PHRM.CNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 30, 2025 | — | — | — | — |
Q3 2025 | Sep 26, 2025 | — | — | — | — |
Q2 2025 | Apr 24, 2025 | — | $-0.00 | — | — |
Q1 2025 | Jan 27, 2025 | — | $-0.00 | — | — |
Q3 2024 | Sep 26, 2024 | $-0.03 | $-0.00 | +85.7% | ✓ BEAT |
Q2 2024 | May 31, 2024 | — | $-0.00 | — | — |
Q2 2024 | Apr 22, 2024 | $-0.03 | $-0.00 | +86.3% | ✓ BEAT |
Q4 2023 | Oct 30, 2023 | $-0.02 | $-0.01 | +40.0% | ✓ BEAT |
Q3 2023 | Sep 28, 2023 | $-0.02 | $-0.02 | +24.4% | ✓ BEAT |
Q2 2023 | Apr 28, 2023 | $-0.02 | $-0.02 | +9.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | — | $-0.01 | — | — |
Q1 2023 | Jan 27, 2023 | $-0.01 | $-0.03 | -200.0% | ✗ MISS |
Q4 2022 | Oct 26, 2022 | $-0.01 | $-0.01 | 0.0% | = MET |
Q2 2022 | May 31, 2022 | — | $0.00 | — | — |
Q2 2022 | Apr 25, 2022 | $-0.06 | $-0.01 | +83.3% | ✓ BEAT |
Q1 2022 | Jan 27, 2022 | $-0.00 | $-0.00 | -79.8% | ✗ MISS |
Q4 2021 | Oct 27, 2021 | $-0.01 | $-0.01 | 0.0% | = MET |
Q2 2021 | Apr 29, 2021 | — | $0.06 | — | — |
Q2 2021 | Apr 29, 2021 | — | $0.00 | — | — |
Q1 2021 | Jan 28, 2021 | — | $0.06 | — | — |
Latest News
Frequently Asked Questions about PHRM.CN
What is PHRM.CN's current stock price?
What is the analyst price target for PHRM.CN?
What sector is PharmaTher Holdings Ltd. in?
What is PHRM.CN's market cap?
Does PHRM.CN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PHRM.CN for comparison